Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
Tarsus Pharmaceuticals announced a definitive agreement to acquire Alkeus Pharmaceuticals for approximately $450 million in upfront consideration, consisting of $270 million in cash and $180 million in stock. The acquisition centers on ALK-001 (gildeuretinol), a Phase 3 oral therapy for Stargardt disease with Breakthrough Therapy and Orphan Drug designations.
Key figures
- Drug Name
- gildeuretinol (ALK-001)
- Deal Value Usd
- 450000000
- Phase Of Trial
- Phase 3
- Milestones
- 350000000
- Stock price
- 61.38
- Upfront cash
- 270000000
- Upfront stock
- 180000000
- Topline data date
- second half of 2029
- Northstar enrollment
- 230
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.